HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

8- (3- amino- 1- piperidinyl)- 7- (2- butyn- 1- yl)- 1- ((4,6- dimethyl- 2- pyrimidinyl)methyl)- 3- methylxanthine

BI 14361 is the (3R)-isomer; structure in first source

Also Known As:

BI 14361

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Alkaloids: 5398
  - Xanthines: 123
    - 8-(3-amino-1-piperidinyl)-7-(2-butyn-1-yl)-1-((4,6-dimethyl-2-pyrimidinyl)methyl)-3-methylxanthine: 1
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - Purinones: 2
        Xanthines: 123
        8-(3-amino-1-piperidinyl)-7-(2-butyn-1-yl)-1-((4,6-dimethyl-2-pyrimidinyl)methyl)-3-methylxanthine: 1

Experts

1.	Hocher, Berthold: 1 article (07/2013)
2.	Klein, Thomas: 1 article (07/2013)
3.	Mark, Michael: 1 article (07/2013)
4.	Pfab, Thiemo: 1 article (07/2013)
5.	Sharkovska, Yuliya: 1 article (07/2013)

Related Diseases

1.	Ischemia 07/15/2013 - "This study evaluated the novel xanthine-based dipeptidylpeptidase-4 inhibitors linagliptin (BI 1356) and BI 14361 in cardiac ischemia. "
2.	Myocardial Ischemia (Ischemic Heart Diseases) 07/15/2013 - "Linagliptin and BI 14361 are able to reduce infarct size after myocardial ischemia. " 07/15/2013 - "The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats."
3.	Infarction (Infarctions) 07/15/2013 - "Male Wistar rats were pretreated with linagliptin or BI 14361 and subjected to ligation of the left anterior descending coronary artery for 30 min. Dipeptidylpeptidase-4 inhibition significantly reduced the infarct size after 7 days (-27.7%, p<0.05) and 8 weeks (-18.0%, p<0.05). " 07/15/2013 - "Linagliptin and BI 14361 are able to reduce infarct size after myocardial ischemia. " 07/15/2013 - "The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats."

Related Drugs and Biologics

1.	Xanthine
2.	Linagliptin
3.	Dipeptidyl-Peptidase IV Inhibitors

Related Therapies and Procedures

1.	Ligation